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glial, neuronal and endothelial markers demonstrating pluripo-
tency of differentiation potential. These findings point towards
an essential role of CD133/Musashi-1+ cells in glioma biology
making these cells a potential target for future therapies. On the
other hand, stem cells are currently evaluated as potential carriers
of anti-glioma therapies. Therefore, the second aim of our studies
was to assess intracerebral distribution patterns of mesenchymal
stroma cells (MSC) after local versus systemic application. Human
MSC (hMSC) were isolated from bone marrow biopsies carried out
for haematological indications. U373-GFP gliomas were generated
by orthotopic implantation. After local application of hMSC,
migration of hMSC towards the tumor was observed. In a second
setting, intravenously administered MSC transfected with a RFP/
Tie-2 promotor gene showed extensive tropism to the glioma.
RFP expression indicated integration of MSC into the intratumoral
vasculature. Therefore, MSC might be valuable candidates as car-
riers for an anti-tumor, especially an anti-vascular gene therapy.
Altogether, stem cells might play roles in the ‘‘cause’’ as well as
in the ‘‘cure’’ of glioma.
doi:10.1016/j.ejcsup.2006.04.049
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Some of the most potent cytotoxic drugs, e.g. ifosfamide, are
hampered in their effectiveness in certain cancers due to severe
side effects in elder patients. A way to circumvent this problem
is to employ gene directed enzyme prodrug therapy by delivering
a second site of drug activation at the tumor site. This concept
was developed using ifosfamide as the prodrug and the metabol-
ising cytochrome P450 subenzyme CYP2B1 for conversion. The
gene was transfected in 293 cells. To protect the genetically mod-
ified cells from the host immune system and, conversely, to pro-
tect the host from the allogenic cells, those were
microencapsulated in sodium cellulose (diameter  0.8 mm). In
an experimental setting, the microcapsules containing CYP2B1
expressing cells were directly injected in pre-established human
pancreatic adenocarcinomas on nude mice. After treatment with
low-dose ifosfamide, 20% CR was achieved. Identical results were
obtained in a syngenic rat pancreatic carcinoma model. Further,
this experimental approach has very successfully been applied
to experimental peritoneal carcinomatosis as well as naturally
occurring breast carcinomas in dogs. For clinical use, a feasibility
study in pigs demonstrated the safety of agiographic intra-arterial
placement into a pancreatic artery. After completion of IRB and
registration with authorities, a clinical phase I/II study in patients
with inoperable pancreatic adenocarcinoma was performed. The
concept proved to be safe. 2/14 patients demonstrated a partial
remission, the reminder was stable. Mean OS was 44 weeks,
one year survival 32%.
doi:10.1016/j.ejcsup.2006.04.050
S50. DEVELOPING STRATEGIES FOR TUMOR VACCINATION
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Vaccination against cancer has had a variable history, with
claims of success often fading into disappointment. The reasons
for this include poor vaccine design, inadequate understanding
of the nature of the immune response, and a lack of objective
measures to evaluate performance. The characterization of
tumor-associated antigens (TAAs) recognized by human T lym-
phocytes in a MHC-restricted fashion has opened new possibili-
ties for specific vaccine approaches to the treatment of human
cancers. Recent findings include vaccine formulation, relevant
knowledge concerning mechanisms of induction of effective
immunity from preclinical models, and translation into clinical
trials. We now have novel vaccine strategies to activate specific
attack on tumor cells and we understand more about activation
and regulation of immunity against cancer (co-stimulation versus
co-inhibition, regulatory T cells). We also have modern assays
using surrogate markers (MHC multimer analysis, IFN-c Elispot
assay) to correlate with clinical effects. Although early clinical
vaccine trials based on synthetic peptides, proteins, ‘naked’
DNA, tumor-RNA, dendritic cells, and recombinant vaccinia
viruses indicate that vaccines can induce immune responses
and tumor regression in some cancer patients, careful study
design and use of standardized clinical and immunological crite-
ria are needed. Basic principles of tumor vaccination and clinical
trials will be discussed.
doi:10.1016/j.ejcsup.2006.04.051
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Disseminated tumor cells in tissue, blood or bone marrow sam-
ples of patients with thyroid carcinoma are detectable by PCR
assays by using different molecular tumor markers. The aim of
our study was to correlate the results of molecular staging with
the patients’ follow-up.
Patients and Methods: Eighty-seven tumor, 43 blood and 14 bone
marrow samples of patients with thyroid carcinomas were
obtained during surgery and subjected to Cytokeratin 20 (CK20)
and PreproGastrin-releasing peptide (PreproGRP) PCR systems.
Results: An expression of CK20 transcripts was detected in all of
the medullary thyroid carcinomas (MTC), 63% of follicular thyroid
carcinomas (FTC), 43% of papillary (PTC) and 17% of anaplastic
(ATC) carcinomas . In FTC and PTC an expression of CK20 was
seen in 54% in primary tumors and in 42% in soft tissue or lymph
node recurrence. 75% of the patients with CK20-positive FTC were
disease-free at follow-up compared to none of the patients with
CK20-negative FTC. PreproGRP was found in 100% of MTC tissue
samples. Overall, disseminated tumor cells of CK20-positive
carcinomas were detected in 33% of the blood samples. In MTC,
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